Jaguar Health Reports Voting Results from January 2023 Special Meeting of StockholdersAccesswire • 01/20/23
Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31stAccesswire • 01/20/23
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies DerivAccesswire • 01/12/23
Sandra M. Swain, MD, FACP, FASCO Joins Jaguar Health's Scientific Advisory BoardAccesswire • 01/11/23
Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from PsAccesswire • 01/10/23
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health IllnessesAccesswire • 01/10/23
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party InvestigatorAccesswire • 12/19/22
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related DiarrheaAccesswire • 12/05/22
Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related DiarrheaAccesswire • 11/21/22
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter FinancialsAccesswire • 11/14/22
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar's Take C.H.A.R.G.E.Accesswire • 10/27/22
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer PatientsAccesswire • 10/26/22
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease IndicationAccesswire • 10/17/22
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) InitiativeAccesswire • 10/12/22
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other PathogensAccesswire • 09/29/22
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29thAccesswire • 09/22/22
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from CholeraAccesswire • 08/30/22
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue StreamAccesswire • 08/25/22
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for ReviewAccesswire • 08/23/22
Jaguar Health, Inc.'s (JAGX) CEO Lisa Conte on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/22/22
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter FinancialsAccesswire • 08/22/22
